RTI Surgical Evolves Into Evergen
RTI Surgical rebrands as Evergen, emphasizing CDMO leadership in regenerative medicine biomaterials.
RTI Surgical has rebranded itself as Evergen, signaling a strategic transformation into a premier CDMO in regenerative medicine. This evolution follows the successful acquisitions of Cook Biotech and Collagen Solutions, solidifying Evergen as the only CDMO capable of offering both allograft and xenograft biomaterials at scale.
The new identity reflects Evergen's commitment to advancing patient-centered innovations. CEO Olivier Visa emphasized the company’s focus on flexible, high-quality solutions to meet diverse therapeutic needs, while Chief People Officer Kim Spooner highlighted the unified culture driving Evergen's growth and its vision for the future.
Reporting on the science, business and regulation shaping the pharmaceutical industry.
Más de Pharma News
Todos los artículos →
Medicus Pharma presenta al FDA el protocolo combinado de fase 2b/3 para Teverelix
Fresenius Kabi recibe una carta de advertencia de la FDA tras fallos en la investigación del procesamiento aséptico en la planta de Melrose Park
Discussion